Gaudium IVF Hit Upper Circuit After Q4 FY26 Results; PAT Jumps 29%

The shares of Gaudium IVF and Women Health Limited hit the upper circuit today after announcing stellar Q4 FY26 results. The company reported strong growth across revenue, EBITDA, and profit during the fourth quarter of FY26. 

The fertility and women’s healthcare platform continued to deliver steady growth momentum in FY26 while also strengthening its technology capabilities through AI-led embryology solutions. 

Gaudium IVF Q4 FY26 Financial Performance 

The company’s revenue from operations for Q4 FY26 stood at ₹30.35 crore, registering a YoY growth of 12.74% compared to ₹26.92 crore in the corresponding quarter last year. Sequentially, revenue grew 23.85% from ₹24.50 crore reported in Q3 FY26. 

EBITDA for the quarter stood at ₹12.17 crore, up 39.56% YoY from ₹8.72 crore. EBITDA margin improved to 40.10% during the quarter compared to 32.39%. 

Looking at the bottom line, profit after tax for Q4 FY26 stood at ₹8.36 crore, rising 29.46% YoY from ₹6.45 crore reported in the year-ago quarter. PAT margin expanded to 27.54%. 

Gaudium IVF Financial Performance for FY26 

For FY26, revenue stood at ₹104.35 crore, registering a growth of 47.56% compared to ₹70.72 crore in FY25. EBITDA increased 31.69% YoY to ₹37.70 crore, while PAT rose 27.69% to ₹24.48 crore. 

The company stated that the strong performance was driven by higher patient volumes at mature hubs, improving operating leverage, and a richer mix of advanced IVF protocols. 

Management Commentary 

Dr. Manika Khanna, Chairperson and Managing Director of Gaudium IVF and Women Health Limited said FY26 marked a defining year for the company as it transitioned into a listed and scalable fertility platform. 

She also stated that IVF treatment continues to remain the core growth engine for the business, supported by the company’s strong clinical success rates.  

Gaudium IVF Share Price Performance 

As of May 29, 2026, at 11:43 PM, Gaudium IVF share price hit the upper circuit and is currently at ₹119.25 per share on the BSE. The current market capitalisation of the company stands at ₹867.98 crore. 

The stock has delivered strong returns of around 51% compared to the IPO issue price of ₹79 per share. 

Gaudium IVF was listed on the stock exchanges on February 27, 2026, at a listing price of ₹83 per share against its IPO issue price of ₹79, delivering a listing gain of around 5%. 

Conclusion 

Gaudium IVF delivered a strong set of Q4 FY26 numbers with healthy growth across revenue and profit. The company maintained a network of 7 hubs and 28 spokes during FY26, while delivering a clinical pregnancy success rate of over 58% on the first IVF attempt. Going forward, the company plans to operationalise 19 new IVF hubs, with 3 hubs expected to become operational soon and a total of 10 hubs targeted in FY27.